BioSpace News Archive

Glenmark Pharmaceuticals, a research-led, integrated global pharmaceutical company, today announced that Alessandro Riva, MD, will join its new innovation company as Chief Executive Officer.

“In a time when the state has numerous competing priorities, we appreciate that Gov. Murphy’s budget proposal preserves charity care funding to provide a safety net for the working poor uninsured, along with other important programs like graduate medical education to ensure that New Jersey has enough clinicians to meet our future care needs.

The Honourable Ginette Petitpas Taylor, federal Minister of Health, accompanied by the Honourable Bill Morneau, Minister of Finance and Dr. Eric Hoskins, Chair of the Advisory Council on the Implementation of National Pharmacare will make an announcement.

Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that management will present at the upcoming Barclays Global Healthcare Conference taking place March 12-14, 2019 in Miami Beach, Florida.

Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company, today announced that Dr. Peter Wrighton-Smith, Chief Executive Officer, is scheduled to present at the following upcoming investor conferences

Inivata, a leader in liquid biopsy, today announces thatPalmetto GBA, a Medicare Administrative Contractor recognized for its molecular diagnostic technology assessment experience through its assessment group, MolDx, has issued its final Coverage Determination for InVisionFirst™-Lung Liquid Biopsy test,

The National Association for Behavioral Healthcare applauds the decision filed in California’s Northern District that opens access to behavioral healthcare services for those who need it.

RM LAW, P.C. announces that a class action lawsuit has been filed on behalf of all persons or entities that purchased AVEO Pharmaceuticals, Inc. between August 4, 2016 and January 31, 2019, inclusive.

Invitae Corporation announced the pricing of an underwritten public offering of 9,000,000 shares of its common stock at a price to the public of $19.00 per share.